ArticleACS omega2026
Effects of Drying on Energetic Materials Produced by Spray Flash Evaporation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spray atomization, particularly spray flash evaporation (SFE), exhibited interesting properties such as a small droplet size and rapid droplet evaporation, which facilitate the recrystallization of energetic materials (EMs) with enhanced physicochemical properties. This study, for the first time, explores the effectiveness of the drying stage after atomization in the SFE technique in removing the solvent and altering the physicochemical properties (crystallinity, size, morphology, and performance) of cyclotrimethylenetrinitramine (RDX), a widely used explosive, when obtained at 160 °C and 40 bar. Two different and successive drying steps were applied to particles. They were first dried directly in the SFE process for a short period, about 1 min following the end of atomization, at a very low pressure of 11 mbar and under dynamic vacuum. Then, particles were exposed to a second ex situ drying under 24 h at 800 mbar and 40 °C. It was found that SFE reduced the particle size as well changing the particle morphology and conserving the crystalline phase. Particles exhibited less regular, nonspherical morphologies, bridge-like structures, and some displayed cavities, likely resulting from buckling associated with fast evaporation and crystallization processes. Particles also showed the presence of a residual solvent (acetone). Unexpectedly, even the second drying process failed to fully eliminate residual acetone, which probably remained trapped within the particles. Results uncover an Ostwald ripening where prolonged drying led to particle growth and cavity disappearance, likely accentuated by the presence of residual solvent, promoting RDX diffusion on the particle surface. Importantly, the morphology and particle size also dictate the sensitivity. Smaller RDX particles with significant surface defects, produced by SFE and drying during a short time, exhibit a lower impact and friction threshold. The second drying step, restoring near-spherical morphology and removing morphology defects while maintaining a lower particle size compared to that of the raw material, raised the impact threshold to 8.5 J while leaving friction and electrostatic discharge sensitivities mainly unchanged. These results pave the way to advance the spray atomization process in EM recrystallization, with a particular emphasis on the final drying stage. Notably, the presence of even trace amounts of residual solvent within the RDX particles can highly influence their physicochemical properties, underscoring the need for precise control of the drying after atomization to optimize particle quality and performance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.